The Current Ratio as of December 2024 (TTM) for Eton Pharmaceuticals, Inc. (ETON) is 1.51

According to Eton Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.51. This represents a change of -1.83% compared to the average of 1.54 of the last 4 quarters.

Eton Pharmaceuticals, Inc. (ETON) Historical Current Ratio (quarterly & annually)

How has ETON Current Ratio performed in the past?

The mean historical Current Ratio of Eton Pharmaceuticals, Inc. over the last ten years is 7.78. The current 1.51 Current Ratio has changed 1.84% with respect to the historical average. Over the past ten years (40 quarters), ETON's Current Ratio was at its highest in in the December 2017 quarter at 16.76. The Current Ratio was at its lowest in in the June 2017 quarter at 0.

Eton Pharmaceuticals, Inc. (ETON) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Eton Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Eton Pharmaceuticals, Inc. (ETON) Average Current Ratio

How has ETON Current Ratio performed in the past?

The current Current Ratio of Eton Pharmaceuticals, Inc. (ETON) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Eton Pharmaceuticals, Inc. (ETON) Current Ratio vs. Peers

How is ETON’s Current Ratio compared to its peers?

Eton Pharmaceuticals, Inc.’s Current Ratio is less than Connect Biopharma Holdings Limited (12.04), less than Acumen Pharmaceuticals, Inc. (10.43), less than Nuvation Bio Inc. (9.57), less than Eledon Pharmaceuticals, Inc. (6.53), less than Eliem Therapeutics, Inc. (0), less than Inhibrx Biosciences, Inc. (4.70), less than Merrimack Pharmaceuticals, Inc. (10.78), less than Celcuity Inc. (10.36), less than Enliven Therapeutics, Inc. (17.44), less than Replimune Group, Inc. (10.11), less than Nuvectis Pharma, Inc. (2.74), less than Lyra Therapeutics, Inc. (3.64), less than Kronos Bio, Inc. (8.32), less than Gossamer Bio, Inc. (6.74), less than Tarsus Pharmaceuticals, Inc. (5.42), less than LianBio (10.06), less than Aldeyra Therapeutics, Inc. (6.80), less than Travere Therapeutics, Inc. (1.71), less than Passage Bio, Inc. (5.15), less than Black Diamond Therapeutics, Inc. (5.55), less than TCR2 Therapeutics Inc. (2.77), less than Harpoon Therapeutics, Inc. (1.89), less than Alector, Inc. (3.29),

Build a custom stock screener for Eton Pharmaceuticals, Inc. (ETON) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eton Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Eton Pharmaceuticals, Inc. (ETON) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Eton Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.